FDA lifts Telcyta hold

Telik (TELK) gained $0.48 (14%) to $3.94 on Monday after announcing that FDA lifted a partial hold on the Phase III ASSIST-5 trial of Telcyta ( TLK286) plus doxorubicin as second-line therapy for platinum-refractory or resistant ovarian cancer. TELK said it would perform an interim analysis of ASSIST-5 data before possibly resuming enrollment late this year or early next. FDA placed the hold on Telcyta in June following the presentation of updated data from other Phase III trials showing median survival was worse in the Telcyta arms than in the control arms (See BioCentury Extra, Tuesday, June 05, 2007). ...